


## Technical Information about 8-Br-2'-O-Me-cAMP-AM

Membrane-permeant, metabolically activatable stimulator of Epac

Update: January 08, 2021 HU



**Abbreviation:** **8-Br-2'-O-Me-cAMP-AM**

Formula	CAS No.	Molecular Weight	UV	BIOLOG Cat. No.
C <sub>14</sub> H <sub>17</sub> BrN <sub>5</sub> O <sub>8</sub> P	[pending]	494.2	λ <sub>max</sub> 264 nm / ε 17000 / pH 7	B 028

**Name:** 8- Bromo- 2'- O- methyladenosine- 3', 5'- cyclic monophosphate, acetoxymethyl ester

**Description:** 8-Br-2'-O-Me-cAMP-AM is an analogue of the natural signal molecule cyclic AMP in which the hydrogen in position 8 of the heterocyclic nucleobase is replaced by bromine and the 2'-hydroxy group has been methylated. In addition the polar phosphate is masked by an acetoxymethyl group.

**Properties:** The acetoxymethyl group of 8-Br-2'-O-Me-cAMP-AM masks the charged polar phosphate and thus makes the molecule highly membrane-permeant. Inside the cell esterases release the more polar 8-Br-2'-O-Me-cAMP (Cat. No. B 022), which is a potent and specific agonist of exchange factors directly activated by cAMP (Epac or cAMP-GEF), a newly discovered receptor for cyclic AMP. Since a free 2'-ribose hydroxyl group in cyclic AMP is essential for stimulation of cAMP-dependent protein kinase (PKA), the methylated structure of 8-Br-2'-O-Me-cAMP-AM is an extremely poor PKA activator and allows for specific discrimination between both signalling pathways.

Phosphate tris(acetoxymethyl)ester, PO<sub>4</sub>-AM<sub>3</sub> (our Cat. No. P 030), is recommended as control reagent in 8-Br-2'-O-Me-cAMP-AM applications to test for side effects of enzymatically released acetic acid and formaldehyde, two metabolites with potential biological functions.

**Specification:** Lyophilized or crystallized solid. Please note that equal concentrations of 8-Br-2'-O-Me-cAMP-AM can appear very different in volume due to sensitivity of the lyophilized form to humidity. Micromolar quantities are determined by UV at λ<sub>max</sub>.

**Purity:** Typical analysis is better than 97% (HPLC / UV / 264 nm) for the mixture of equatorial and axial isomers. The product is not sterile and has not been tested for endotoxins.

**Solubility/Application:** Due to its rather high lipophilicity, the solubility of 8-Br-2'-O-Me-cAMP-AM in water or buffers is limited. We suggest to use a small amount of anhydrous organic solvent such as anhydrous DMSO or DMF for preparation of 1-100 mM stock solutions, and to dilute with water or buffer down to the concentrations required. In some cases, especially at high concentrations (~ 1mM), Pluronic® F-127 (Molecular Probes) can be useful to facilitate solubilization in water or physiological media. Please keep in mind that due to the high potency of 8-Br-2'-O-Me-cAMP-AM relatively low concentrations (0.005-0.1 mM) should be sufficient, and be sure to check for DMSO/DMF tolerance in your system. Since 8-Br-2'-O-Me-cAMP-AM is bioactivated by esterases, application to cell cultures should be performed without serum supplements (even heat-inactivated serum still contains active esterases!) in the media for at least 15 minutes. Otherwise, serum esterases may strongly reduce the cell-loading efficacy. Please rinse tube walls carefully and preferably use ultrasonic or vortex to achieve total and uniform mixing.

**Stability and Storage:** 8-Br-2'-O-Me-cAMP-AM is sufficiently stable to be shipped at ambient temperature, however, it should be stored in the freezer (-20°C necessary, -80°C recommended). Please note that aqueous solutions are rather labile and should be freshly prepared immediately before use. Stock solutions in anhydrous DMSO or DMF should be relatively stable when stored frozen at -20°C to -80°C.

**Toxicity and Safety:** Since cyclic AMP has multiple tasks in every organism it is very likely that lipophilic cAMP analogues will interfere with many cell regulation processes *in vivo*. However, due to the rather small quantities to work with no health hazards have been reported. Nevertheless please keep in mind that the *in vivo* properties of this compound are not sufficiently characterized up to now. Avoid skin contact or ingestion and allow only trained personnel to handle the product.

Our products are designed, developed and sold for research purposes only. They are intended for *in vitro* and nonhuman *in vivo* laboratory applications. Any other use requires approval of health authorities.

**Not for drug, household or related uses!**

#### **Selected References for 8-Br-2'-O-Me-cAMP-AM:**

Komai, A.M.; Brännmark, C.; Musovic, S.; Olofsson, C.S., *J. Physiol.*, **592**, 5169 – 5186 (2014): " PKA-independent cAMP Stimulation of White Adipocyte Exocytosis and Adipokine Secretion: Modulations by Ca<sup>2+</sup> and ATP"

Chepurny, O.G.; Bertinetti, D.; Diskar, M.; Leech, C.A.; Afshari, P.; Tsalkova, T.; Cheng, X.; Schwede, F.; Genieser, H.-G.; Herberg, F.W.; Holz, G.G., *Mol. Endocrinol.*, **27**, 1267-1282 (2013): "Stimulation of Proglucagon Gene Expression by Human GPR119 Enteroendocrine L-Cell Line GLUTag"

Nicol, X.; Hong, K.P.; Spitzer, N.C., *PNAS*, **108**, 13776 - 13781 (2011): "Spatial and Temporal Second Messenger Codes for Growth Cone Turning"

Börner, S.; Schwede, F.; Schlipp, A.; Berisha, F.; Calebiro, D.; Lohse, M.J.; Nikolaev, V.O., *Nat. Protoc.*, **6**, 427 - 438 (2011): "FRET Measurements of Intracellular cAMP Concentrations and cAMP Analog Permeability in Intact Cells"

#### **Selected References for specific Epac agonists:**

Kopperud, R.; Krakstad, C.; Selheim, F.; Døskeland, S. O., *FEBS Lett.*, **546**, 121 - 126 (2003): "cAMP Effector Mechanisms. Novel Twists for an 'Old' Signaling System"

Rehmann, H.; Schwede, F.; Døskeland, S.O.; Wittinghofer, A.; Bos, J.L., *J. Biol. Chem.*, **278**, 38548 - 38556 (2003): "Ligand-mediated Activation of the cAMP-responsive Guanine Nucleotide Exchange Factor Epac"

Christensen, A.E.; Selheim, F.; de Rooij, J.; Dremier, S.; Schwede, F.; Dao, K.K.; Martinez, A.; Maenhaut, C.; Bos, J.L.; Genieser, H.-G.; Døskeland, S.O., *J. Biol. Chem.*, **278**, 35394 - 35402 (2003): "cAMP Analog Mapping of Epac1 and cAMP-Kinase. Discriminating Analogs Demonstrate that Epac and cAMP-Kinase Act Synergistically to Promote PC-12 Cell Neurite Extension"

Eliasson, L.; Ma, X.S.; Renström, E.; Barg, S.; Berggren, P.O.; Galvanovskis, J.; Gromada, J.; Jing, X.J.; Lundquist, I.; Salehi, A.; Sewing, S.; Rorsman, P., *J. Gen. Physiol.*, **121**, 181 - 197 (2003): "SUR1 Regulates PKA-independent cAMP-induced Granule Priming in Mouse Pancreatic B-cells"

Rangarajan, S.; Enserink J.M.; Kuiperij, H.B.; de Rooij, J.; Price, L.S.; Schwede, F.; Bos, J.L., *J. Cell Biol.*, **160**, 487 - 493 (2003): "Cyclic AMP Induces Integrin-mediated Cell Adhesion Through Epac and Rap1 Upon Stimulation of the  $\beta_2$ -Adrenergic Receptor"

Kang, G.; Joseph, J.W.; Chepurny, O.G.; Monaco, M.; Wheeler, M.B.; Bos, J.L.; Schwede, F.; Genieser, H.-G.; Holz, G.G., *J. Biol. Chem.*, **278**, 8279 - 8285 (2003): "Epac-selective cAMP Analog 8-pCPT-2'-O-Me-cAMP as a Stimulus for Ca<sup>2+</sup>-induced Ca<sup>2+</sup> Release and Exocytosis in Pancreatic  $\beta$ -Cells"

Christensen, A.E.; de Rooij, J.; Kopperud, R.; Nilsen, O.K.; Dao, K.K.; Schwede, F.; Bos, J.L.; Genieser, H.-G.; Døskeland, S.O., Abstracts of the 13th Protein Kinase Symposium, Oslo/Norway, 2002: "Comparison of the cAMP Binding Sites of EPAC-1 and cAMP-Kinase"

Enserink J.M.; Christensen, A.E.; de Rooij, J.; van Triest, M.; Schwede, F.; Genieser, H.-G.; Døskeland, S.O.; Blank, J.L.; Bos, J.L., *Nature Cell Biol.*, **4**, 901 - 906 (2002): "A novel Epac-specific cAMP Analog Demonstrates Independent Regulation of Rap1 and ERK"

#### **Selected Reference for 8-Br-2'-O-Me-cAMP:**

Christensen, A.E.; Selheim, F.; de Rooij, J.; Dremier, S.; Schwede, F.; Dao, K.K.; Martinez, A.; Maenhaut, C.; Bos, J.L.; Genieser, H.-G.; Døskeland, S.O., *J. Biol. Chem.*, **278**, 35394 - 35402 (2003): "cAMP analog mapping of Epac1 and cAMP-Kinase. Discriminating Analogs Demonstrate that Epac and cAMP-Kinase Act Synergistically to Promote PC-12 Cell Neurite Extension"

#### **Selected Reference for AM-ester:**

Kruppa, J., Keely, S., Schwede, F., Schultz, C., Barrett, K.E. and Jastorff, B., *Bioorg. Med. Chem. Lett.* **7**, 945 - 948 (1997): "Bioactivatable Derivatives of 8-Substituted cAMP- Analogues"